The Manufacturers Life Insurance Company Takes Position in Hemab Therapeutics Holdings, Inc. $COAG

The Manufacturers Life Insurance Company bought a new stake in shares of Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) during the 2nd quarter, Holdings Channel.com reports. The firm bought 18,720 shares of the company’s stock, valued at approximately $688,000.

Other large investors have also recently added to or reduced their stakes in the company. Squarepoint Ops LLC acquired a new stake in Hemab Therapeutics in the 2nd quarter valued at $230,000. Braidwell LP acquired a new position in shares of Hemab Therapeutics during the second quarter worth about $5,877,000. Finally, Citadel Advisors LLC acquired a new position in shares of Hemab Therapeutics during the second quarter worth about $19,226,000.

Hemab Therapeutics Stock Performance

Hemab Therapeutics stock opened at $40.47 on Tuesday. Hemab Therapeutics Holdings, Inc. has a 1 year low of $23.00 and a 1 year high of $55.42. The business has a 50-day simple moving average of $46.34. The company has a market cap of $1.89 billion and a P/E ratio of -1.63.

Hemab Therapeutics (NASDAQ:COAG) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17). As a group, equities analysts expect that Hemab Therapeutics Holdings, Inc. will post -3.09 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently issued reports on COAG. Wedbush increased their target price on Hemab Therapeutics from $55.00 to $64.00 and gave the company an “outperform” rating in a research note on Wednesday, August 12th. Evercore started coverage on Hemab Therapeutics in a research report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 price target on the stock. Jefferies Financial Group upped their price target on Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, July 13th. HC Wainwright increased their price objective on shares of Hemab Therapeutics from $52.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Finally, Zacks Research upgraded shares of Hemab Therapeutics to a “hold” rating in a research note on Wednesday, May 27th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $51.40.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious and underserved bleeding disorders. The company aims to create therapies that address limitations of existing approaches, including the need for frequent administration and the challenges associated with complex blood-product-based treatments.

Its lead investigational program, HMB-001, is being developed for Glanzmann thrombasthenia, a rare inherited disorder in which platelets do not function properly and can cause severe bleeding.